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Abstract Human and chimpanzee CD4+ T cells differ
markedly in expression of the inhibitory receptor Siglec-5,
which contributes towards differential responses to activat-
ing stimuli. While CD4+ T cells from both species are
equally susceptible to HIV-1 infection, chimpanzee cells
survive better, suggesting a cell-intrinsic difference. We
hypothesized that Siglec-5 expression protects T cells from
activation-induced and HIV-1-induced cell death. Transduc-
tion of human CEM T cells with Siglec-5 decreased cell
responses to stimulation. Following HIV-1 infection, a
higher percentage of Siglec-5-positive cells survived, sug-
gesting relative resistance to virus-induced cell death. Con-
sistent with this, we observed an increase in percentage of
Siglec-5-positive cells surviving in mixed infected cultures.
Siglec-5-transduced cells also showed decreased expression
of apoptosis-related proteins following infection and re-
duced susceptibility to Fas-mediated cell death. Similar
Siglec-5-dependent differences were seen when comparing
infection outcomes in primary CD4+ Tcells from humans and
chimpanzees. A protective effect of Siglec-5 was further sup-
ported by observing greater proportions of circulating CD4+ T
cells expressing Siglec-5 in acutely infected HIV-1 patients,
compared to controls. Taken together, our results suggest that
Siglec-5 expression protects T cells from HIV-1- and
apoptosis-induced cell death and contributes to the different
outcomes of HIV-1 infection in humans and chimpanzees.
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Introduction
Nonhuman primate models have contributed greatly to our
understanding of HIV-1 pathogenesis and have been invalu-
able for testing the efficacy of experimental vaccines and
drug regimens [1, 2]. There are, however, surprising differ-
ences in outcomes of HIV-1 infection between humans and
captive chimpanzees.
The major circulating clade of HIV-1 arose via cross-
species transfer of a chimpanzee SIVcpz and ultimately
resulted in rapid progression to AIDS in the great majority
of untreated infected humans [3]. Endemic SIVcpz infection
in wild chimpanzees can cause a less severe AIDS-like
syndrome, with CD4+ T cell depletion, lymphatic tissue
destruction, and premature death [4]. However, experimen-
tal infections of chimpanzees with HIV-1 only rarely caused
AIDS [5], with the great majority of HIV-1-infected chim-
panzees still surviving >20 years later. Several explanations
have been put forward, including a lack of CD4+ T cell
bystander apoptosis, a relative resistance of chimpanzee
monocyte macrophages to infection with primary isolates,
low HIV-1-specific cytotoxic T lymphocyte responses, low
immune activation, and preservation of CD4+ T helper
function (reviewed in [6]).
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Experimental SIV infection in other nonhuman primate
models has led to a better understanding of the pathogenesis
of HIV-1 in humans (recently reviewed in [7]). For example,
it appears that hyperimmune activation that occurs in
patients infected with HIV-1 is driven by factors such as
loss of gut-associated CD4+ T cells with loss of GI mucosal
integrity and translocation of microbial products, differential
expression of pro-inflammatory factors, and differences in
upregulation of HIV coreceptors [8]. These systemic factors
are doubtless important, but cell-intrinsic factors involving
the infected CD4+ T cells themselves also contribute.
One host difference between human and chimpanzee
CD4+ T cells is much higher expression of inhibitory
Siglecs (sialic acid-binding immunoglobulin-like lectins) in
the latter [9]. Siglecs are a subfamily of I-type lectins capable
of modulating immune cell activation and death. Most of the
CD33-related Siglecs have inhibitory ITIM motifs in their
cytosolic tails, which recruit Src homology region 2 domain-
containing phosphatases (SHPs) SHP-1 and SHP-2, thus lim-
iting activation pathways stimulated by tyrosine kinases [10].
Siglecs also appear to be involved in apoptotic and non-
apoptotic cell death and may regulate immune responses by
modulating the life span of cells of the innate immune
system [11]. Siglec-10, for example, protects host cells
against lethal responses to pathological cell death and helps
discriminate danger versus pathogen-associated molecular
patterns [12]. In the context of HIV-1 infection, a recent
study showed upregulation of Siglec-6 on tissue-like mem-
ory B cells of infected individuals [13].
Prior to the availability of antiviral treatments, HIV-1
infection in humans almost universally led to AIDS and
death within less than 5–10 years. The marked difference
in outcomes of humans versus captive chimpanzees infected
with HIV-1 remains unexplained and is likely due to com-
plex and multifaceted interactions between virus and host-
specific factors. We have recently shown, using multiple
approaches, that chimpanzee T cells are less responsive to
stimulation than human T cells and that this difference
correlates with Siglec-5 expression [14]. Based on these
observations, and on the fact that CD4+ T cells from chim-
panzees and humans are equally susceptible to HIV-1 infec-
tion in vitro [15, 16], we sought to determine whether a
Siglec-mediated cell-intrinsic mechanism contributes to dif-
ferences in outcomes of HIV-1 infection in CD4+ T cells.
Materials and methods
CEM cell culture and nucleofection The CEM T leukemia
cell line (American Type Culture Collection, Manassas, VA)
was maintained in RPMI 1640 medium (Gibco-Invitrogen,
Carlsbad, CA) supplemented with 1 mM L-glutamine, 50 U/
mL penicillin, 50 μg/mL streptomycin, and 10 % (vol/vol)
fetal bovine serum (complete medium). For generation of
stable clones expressing Siglec-5, 5×106 cells were nucleo-
fected using the Human T cell Nucleofector Kit (Amaxa,
Gaithersburg, MD) according to the manufacturer's proto-
col. Cells were then incubated for 72 h and analyzed for
Siglec-5 expression. The Siglec-5-positive population was
then sorted by flow cytometry (MoFlo, XDP, Beckman
Coulter, Brea, CA) into Siglec-5-positive and negative
subpopulations.
Primary CD4+ lymphocyte isolation and stimulation Chim-
panzee blood samples were collected into EDTA-containing
tubes at the Yerkes National Primate Center (Atlanta, GA)
and shipped on ice overnight to the University of California
San Diego, La Jolla, CA. Human blood was collected from
healthy volunteer donors, with approval from the University
of California San Diego Institutional Review Board. These
samples were collected into identical EDTA-containing
tubes and stored overnight on ice to ensure similar treatment
conditions. Total CD4+ T cells were isolated by negative
selection from buffy coats using the RosetteSep cell separa-
tion procedure (StemCell Technologies, Vancouver, BC,
Canada) followed by density gradient centrifugation with
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO). Resulting
cell preparations were routinely >95 % positive for CD4+
expression by flow cytometry. The isolated cells were cul-
tured in complete medium. To induce cell stimulation, 2–4×
106 cells per 2 mL medium were distributed into flat-bottom
wells of a six-well, nontissue culture-treated plate that was
precoated with anti-CD3 (5–50 ng/mL, clone HIT3a) plus
anti-CD28 (0.2 μg/mL) monoclonal antibodies (BD Bio-
sciences, San Jose, CA). The cells were maintained at a
concentration of 3–5×106 cells per well in complete medi-
um for the remainder of the culture period (13–14 days).
Cell staining and flow cytometry analysis The purity of
CD4+ lymphocyte preparations and Siglec-5 expression
were monitored by direct staining with FITC-conjugated
anti-CD4 and/or APC-conjugated anti-Siglec-5 antibodies
(BD Biosciences). TRAIL/DR5 expression was monitored
using PE-conjugated anti-TRAIL and anti-DR5 antibodies
(eBioscience, San Diego, CA). Simple cell surface staining
was performed for 30 min at 4 °C per manufacturer's
instructions with cell aliquots containing 0.5×106 to 1×
106 cells. For intracellular HIV Gag (p24) analysis, cells
were washed in calcium-free and magnesium-free Dulbec-
co's phosphate-buffered saline (PBS; Mediatech, Herndon,
VA), then fixed and permeabilized following the manufac-
turer's instructions with Cytofix/Cytoperm Buffer (BD Phar-
mingen, San Diego, CA). After washing with Perm/Wash
Buffer (BD Pharmingen), cells were incubated for 30 min
with KC57-RD1 antibody (Beckman Coulter, Fullerton,
CA). Cells were then washed again with Perm/Wash buffer
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and stored in 0.5 % formaldehyde at 4 °C until data acqui-
sition on a FACSCalibur (BD Biosciences). For CFSE la-
beling, 1–2×106 PBMCs were labeled with 5 μM CFSE
(Invitrogen, Carlsbad, CA), incubated for 15 min at 37 °C,
rested on ice for 5 min, and then washed. CFSE content was
analyzed by flow cytometry at various time points. Cell
viability at the end of culture was monitored using ethidium
homodimer-1 staining, following the manufacturer's proto-
col (LIVE/DEAD Viability/Cytotoxicity kit, Invitrogen).
Data were analyzed with FlowJo software.
Virus infection Infectious virus stocks of the NL4-3
strain of HIV-1 were prepared by transfecting plasmid DNA
(NIH AIDS Research and Reference Reagent Program, Ger-
mantown, MD) into the CEM T cells with Lipofectin Trans-
fection Reagent (Invitrogen) and harvesting supernate at the
time of peak viral replication and spread. Aliquots of 2–4×106
cells were incubated with 0.5 mL of the NL4-3 virus stock for
4–6 h at 37 °C at multiplicities of infection of 0.01 to 0.5
TCID50 per cell. After infection, excess virus was removed by
extensive washing with PBS plus 2 % fetal calf serum. Cells
were stimulated as described above, and virus infection was
monitored at different time points during culture. Productive
HIV replication was assessed by quantifying the amount of
soluble p24 antigen released into culture supernatants by ELISA
(Abbott, Abbott Park, IL, and PerkinElmer, Boston, MA).
Immunoreceptor phosphorylation and cell death-related
proteome arrays The Human Phospho-immunoreceptor Ar-
ray and the Human Apoptosis Antibody Array (both from
R&D Systems, Minneapolis, MN, USA) allow for the si-
multaneous detection of 59 different phosphorylated immu-
noreceptors or the relative expression of 35 apoptosis-
related proteins. Briefly, cell lysates from CEM cells were
diluted with array buffer, added to a four-well multidish and
incubated overnight at 2–8 °C. After washing, antibody
conjugated to horseradish peroxidase was added, and
chemiluminescence was quantified after 2 h by scanning
the developed X-ray film on a transmission-mode scanner
according to the manufacturer's recommendations.
Susceptibility to anti-Fas-mediated cell death 1×105 CEM
cells were plated into each well of a 96-well tissue culture
plate and treated with varying concentrations (5–20 μg/mL)
of an activating clone of anti-Fas antibody (clone CH11,
Millipore, Temecula, CA). The percent killing was calculat-
ed by comparing the number of viable cells in untreated
wells versus the number of viable cells in treated wells after
24 h in culture.
HIV-infected patient sample collection and analysis The
San Diego First Choice program was approved by the local
Human Research Protections Program and enrolled
participants from July 2010 to April 2011. At enrollment,
participants underwent a point-of-care rapid antibody test
(Oraquick Advance rapid HIV, OraSure Technologies, Inc.,
Bethlehem, PA). If this test was positive, then confirmation
and HIV staging was performed using Western blot (Cam-
bridge Biotech, distributed by Ortho Diagnostics), plasma
viral load determination (Cobas Amplicor HIV-1 test, Roche
Molecular Systems, Pleasanton, CA), and detuned HIV EIA
(Vironostika LS EIA, bioMerieux Inc, Durham, NC, and
Vitros LS EIA, Ortho-Clinical Diagnostics, Inc., UK). All
study participants had 2 mL whole blood drawn into an
EDTA test tube and washed with Wash Buffer (1 L PBS,
10 mL 1 M sodium azide, 20 mL filtered heat-inactivated
fetal bovine serum, adjusted to pH7.2), then centrifuged for
5 min at 300×g to allow collection of the buffy coat layer.
Washed whole blood (100 μL) was then stained with a
fluorescent Ab mixture (FITC/Siglec-5, PE/CD45RO, Per-
CP/CD4, PE-Cy7/CD38, APC/CD27, APC-Cy7/CD3, and
Pac-Blue/CD8) before evaluation on a FACS Canto II (BD
Biosciences, San Jose, CA). Acquired data were compen-
sated using DIVA software, and analysis was performed
with FlowJo software (Ashland, OR).
Results
CEM cells expressing Siglec-5 survive better in HIV-1-
infected cultures We have previously shown that human
and chimpanzee cells differ in expression levels of
Siglec-5 and that higher expression correlates with de-
creased response to activating stimuli [14]. We hypoth-
esized that Siglec-5 would also protect T cells from
HIV-1-induced cell death, by dampening responses of
activated cells to virus infection. To address this, a
mixed population of CEM cells positive and negative
for Siglec-5 expression was infected in vitro with the
HIVNL4-3 clone. Productive infection was evaluated in
each Siglec-5 subpopulation by measuring released HIV
Gag (p24) at different time points and also by detecting
the expression of intracellular p24 7 days after infection.
Both showed similar levels of productive infection, with
∼30 % of cells expressing intracellular p24 (Fig. 1a)
and similar levels of p24 being released in the culture
supernatant (Fig. 1b). The percentage of cells positive
for Siglec-5 increased over time in HIV-1-infected cul-
tures, suggesting that Siglec-5-positive cells show en-
hanced survival following HIV-1 infection (Fig. 1c). To
further support the hypothesis that Siglec-5 expression
enhanced cell survival and to identify a potential mech-
anism, we measured relative expression of 35 apoptosis-
related proteins in Siglec-5-positive and negative CEM
subsets. Siglec-5-negative cells, some of which were
infected with HIV-1, showed increased expression of
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several apoptosis-related proteins, including the active
form of caspase-3, and TRAILR2/DR5 (Fig. 1d).
Siglec-5-positive cells were also more resistant to Fas-
mediated cell death, induced by antibody cross-linking
and activation of the membrane Fas (Fig. 1e). These
observations support the hypothesis that Siglec-5 expres-
sion, either directly or indirectly, by affecting the ex-
pression of other cofactors, enhances T cell survival
during HIV infection.
Siglec-5 expression in CEM T cells alters the pattern of
immunoreceptor phosphorylation and decreases TNF
production in response to stimulation In order to identify
potential pathways involved, CEM T cells were trans-
fected with a Siglec-5 expression plasmid and activated
with PHA. The relative phosphorylation of >50 immu-
noreceptors in cells with or without activation was then
analyzed using an immunoblot array. The CEM subset
expressing Siglec-5 had fewer immunoreceptors show-
ing tyrosine phosphorylation (Fig. 2a), suggesting a
dampened response to PHA stimulation. Of note,
Siglec-5 itself was phosphorylated upon activation.
Consistent with an inhibitory role, expression of
Siglec-5 in CEM cells also resulted in lower percen-

















































Fig. 1 CEM cells expressing Siglec-5 survive better in HIV-1-infected
cultures. Mixed population of CEM cells positive or negative for
Siglec-5 expression were infected with the NL4-3 clone of HIV. a
7 days later, uninfected control (top) and infected cells (bottom) were
stained for intracellular p24 expression and analyzed by flow cytom-
etry. b Supernatant from Siglec-5 positive (closed circles) and Siglec-5
negative (open squares) was collected at multiple time points after
HIV-1 infection and analyzed for p24 content by ELISA. c Percentages
of Siglec-5-positive versus Siglec-5-negative cells in uninfected and
infected cultures over time (only live cells as determined by FSC and
SSC gating are included in the analysis). d Cells were collected on day
7, and relative expression of different apoptosis-related proteins was
measured using an antibody array. The graph depicts proteins that
showed greater than 1.5-fold difference in expression in Siglec-5-
negative cells over Siglec-5-positive cells. e CEM cells were treated
with an activating anti-Fas antibody for 24 h. Percent killing was
determined by comparing the number of viable cells in treated versus
untreated wells. Error bars represent SEM, n03
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Chimpanzee CD4+ T cells with Siglec-5 expression survive
better than humanCD4+ Tcells followingHIV-1 infection We
next asked if similar results would be observed in pri-
mary T cells that naturally express Siglec-5. CD4+ T
cells were isolated from human (more than 99 %
Siglec-5 negative) and chimpanzee (more than 99 %
Siglec-5 positive) whole blood and infected with HIV-1,
and both human and chimpanzee cells were stimulated
with a high dose of anti-CD3/CD28 antibodies. Produc-
tive viral infection and cell viability were monitored on
multiple days postinfection. The percentage of CD4+ T
cells productively infected did not differ significantly
between human and chimpanzee samples (Fig. 3a). There
was, however, a significant difference in the number of
surviving cells at the end of culture (14 days postinfec-
tion), with chimpanzee cells having a significantly better
rate of survival (Fig. 3b and c). To determine if the
increased survival in chimpanzee cell cultures was due
to cell-intrinsic or cell-extrinsic mechanisms, chimpanzee
CD4+ T cells were labeled with CFSE and then mixed at
a ratio of 1:1 with unlabeled human CD4+ T cells. A portion
of the mixed culture was infected with HIV, both infected and
uninfected cultures were stimulatedwith anti-CD3/CD28 anti-
bodies, and the relative percentage of cells in each population
(CFSE+ and CFSE−) was monitored for 14 days. As shown in
Fig. 3d and e, chimpanzee cells survived better following
HIV-1 infection, even within the same culture as human cells.
In striking contrast, there was an increase in percentage of
human cells in the absence of HIV infection, due to their
increased proliferation, as anticipated from our previous work.
These results point to a cell-intrinsic mechanism being respon-
sible for the increased survival of chimpanzee cells following
HIV-1 infection.
Increased cell death of HIV-infected human CD4+ T cells
is associated with increased expression of apoptosis-
related proteins Next, we examined potential apoptosis-






































Fig. 2 Divergent pattern of immunoreceptor phosphorylation and
decreased TNF production in response to stimulation in CEM cells
expressing Siglec-5. CEM cells were nucleofected with a Siglec-5
expression plasmid and sorted into homogeneous populations of
Siglec-5-positive and Siglec-5-negative cells. a Cells were activated
with PHA for 4 h and the cell lysate collected. Lysate from stimulated
and unstimulated cells was added to phospho-immunoreceptor
antibody array, and immunoblot image analyzed. The graph shows a
change in pixel density of stimulated cells above unstimulated cell
control. b Mixed population of CEM cells positive or negative for
Siglec-5 expression were stimulated with PMA and anti-CD3. Intra-
cellular TNF production was analyzed 4 h later by flow cytometry.
Error bars represent SEM, n04
Fig. 3 Chimpanzee CD4+ T cells expressing Siglec-5 survive better
than human CD4+ T cells in HIV-1-infected cultures. Human and
chimpanzee CD4+ T cells were isolated from whole blood, infected
with HIV-1, and stimulated with anti-CD3/CD28. a Intracellular p24
expression was monitored on days5 and 8 postinfection by flow
cytometry. b Top panel: representative absolute numbers of viable cells
in human- and chimpanzee-infected or uninfected cultures over time.
Bottom panel: The percentage of live cells at day14 of culture was
determined by flow cytometry (n05, error bars represent SEM). c
Representative panels of human and chimpanzee cultures with and
without HIV infection. Numbers on the top right corner represent
absolute number of viable cells (as determined by forward and side
scatter gating) collected for a specified amount of time. Data represen-
tative of three different comparisons. d Chimpanzee CD4+ T cells were
labeled with CFSE and then mixed at a ratio of 1:1 with human CD4+
T cells, infected with HIVor not as a control, and stimulated with anti-
CD3/CD28. Percentage of cells in each population (CFSE+ and CFSE
−) was monitored for 14 days. Histograms depict the percentage of live
cells that are CFSE positive and CFSE negative at day0 and at the end
of culture (day14). e Graphs depict the percentage of each population
(CFSE+ and CFSE−) over time in uninfected cultures (top) and cul-
tures infected with HIV-1 (bottom). Data shown are representative of
three experiments
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and chimpanzee CD4+ T cells, by analyzing the expression
profiles of 35 apoptosis-related proteins using a proteome
array. In agreement with data obtained with CEM cells
expressing Siglec-5, we observed lower levels of expression
of the active form of caspase-3, Fas, and TRAIL receptors 1
and 2 in chimpanzee cells that naturally express Siglec-5
(Fig. 4a), when compared to expression levels in human
cells. Chimpanzee cells also demonstrated significantly low-
er surface level expression of DR5 and TRAIL 10 days after
infection (Fig. 4b), in agreement with previous reports
showing increased susceptibility to apoptosis in human
cells when compared to chimpanzee cells [16, 17].
Attempts at siRNA-mediated knockdown of Siglec-5 did
not work in primary chimpanzee T cells, due to upregu-
lation of Siglec-5 mRNA following cell activation, and
the toxicity of siRNAs in primary cells in long-term
studies (data not shown).
Enrichment of CD4+ T cells expressing Siglecs in human
CD4+ T cell cultures infected with HIV-1 and in HIV-1-
infected patient samples To directly assess whether Siglec
expression in human CD4+ T cells would improve cell
survival, we took advantage of the fact that a minor subset
of CD4+ T cells (usually less than 1 %) in some humans do
express members of the CD33-related family of receptors.
We hypothesized that this minor subpopulation would be
enriched following HIV-1 infection. In order to increase the
detection of such a minor population, cells were stained for
expression of two members of the Siglec family: Siglec-5
and Siglec-9, both of which are inhibitory. Purified human
CD4 T cells were infected with HIV-1, stimulated with anti-
CD3/CD28, and cultured for 8 days, and the percentage of
CD4+ T cells expressing intracellular p24 and/or Siglecs 5
and 9 was analyzed by flow cytometry and compared to the
cells expressing Siglecs in uninfected cultures. Cultures
from three different individuals showed an increase in the
small percentage of Siglec-expressing cells following HIV-1
infection (Fig. 5a and b). The data suggest that Siglec-
expressing cells are better able to survive in HIV-1-
infected cultures, resulting in enrichment of these cells, as
the majority of cells dying are non-Siglec-expressing cells.
We do not believe that Siglec-5-positive cells are expanding
with HIV infection, since expression of Siglec-5 in human
cells is strongly repressed, as suggested by our prior studies,
which have shown that Siglec-5 expression is not induced
upon cell activation nor upon treatment with certain epige-
netic modifying drugs (data not shown). It is still possible,
however, that in the three individuals used in our study,
Siglec expression may not be as strongly repressed as in
other individuals.
To determine if enrichment of Siglec-5-positive cells also
occurs in vivo, the percentage of CD4+ cells with Siglec-5
expression was analyzed by flow cytometry in peripheral blood
samples from patients with recent HIV infection (Table 1).
Compared to HIV-negative controls, such patients demonstrat-
ed a significant increase in percentage of CD4+ T cells that
expressed Siglec-5 (Fig. 5c).
Discussion
Since the discovery of HIV-1 as the causative agent of
AIDS, the use of chimpanzees as disease models has been
insightful, challenging, and controversial. Based on the fact
that chimpanzees were equally susceptible to infection by
HIV, there was great hope that they would be useful as an
animal model for disease pathogenesis [18, 19]. However,
despite similar infection susceptibility and virus production,
the outcome of HIV-1 infection was quite different in these
animals [5, 15, 17] with the great majority surviving without

































Fig. 4 Increased cell death of human CD4+ T cell is associated with
increased expression of apoptosis-related proteins. HIV-1-infected hu-
man and chimpanzee CD4+ T cells were collected 8 days after infec-
tion and analyzed for expression of apoptosis-related proteins. a
Relative expression of different apoptosis-related proteins was mea-
sured using an antibody array. The graph depicts proteins that showed
greater than 1.5-fold difference in increased expression in HIV-1-
infected human over chimpanzee CD4+ T cells. One comparison with
2×106 cells from each species was performed. b Surface expression of
TRAIL and DR5 were analyzed at day8 postinfection in HIV-1-
infected human and chimpanzee CD4+ T cells. Error bars represent
SEM, n04
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AIDS for >20 years and many still alive today. The excep-
tion that actually proves the rule was an unusual strain that
evolved to cause AIDS in a multiply infected chimp [20]
and proved highly pathogenic when transferred to other
chimps [21]. Over the years, the literature has accumulated
conflicting reports regarding cytopathic effects of HIV in
chimpanzee CD4+ T cells, virus replication capacity, and
CD8 T cell-killing ability [16, 22–26]. Our study addresses
cell-intrinsic differences between human and chimpanzee
CD4+ T cells that can clarify differences in their ability to
succumb to HIV-1 infection.
Here, we show that a human T cell line expressing
Siglec-5 shows both a reduced response to activating stimuli
and an intrinsic advantage in cell survival following HIV-1
infection. The decreased response to activating stimuli was
associated with higher tyrosine phosphorylation of activat-
ing receptors, such as CD3 epsilon and NKp46, in Siglec-5-
negative CEM cells. The increased survival of Siglec-5-
positive cells in HIV-1-infected cultures was associated with
decreased expression of apoptosis-related proteins, like the
active form of caspase-3, and TRAILR2/DR5. How does
Siglec-5 expression confer an intrinsic advantage in terms of
cell survival following HIV-1 infection in vitro? Siglec-5
has been previously shown to mediate SHP-1- and/or SHP-
2-dependent signaling even in the absence of tyrosine phos-
phorylation [27] and may affect T cell survival via this
mechanism. More recently, the absence of SHP-1 has been
shown to increase Fas-induced cell death [28]. T cells with
Siglec-5 expression demonstrated a similar functional phe-
notype, consistent with SHP-1 recruitment and inhibition of
apoptosis. We cannot of course rule out the possibility that
Siglec expression is indirectly correlated with protection via












Fig. 5 Enrichment of CD4+ T cells expressing Siglecs in human CD4
+ T cell cultures infected with HIV-1 and in HIV-1-infected patient
samples. a Purified primary human CD4+ T cells were infected with
HIV-1 or left uninfected as a control, and stimulated with anti-CD3/
CD28. After 8 days, the percentage of CD4+ T cells expressing
intracellular p24 and both inhibitory Siglecs 5 and 9 was analyzed by
flow cytometry and compared to the percentage of Siglec-expressing
cells in uninfected cultures. b The graph depicts summary data of HIV-
1 infection of CD4+ T cells from three different individuals as de-
scribed above. The data shown represent the percentage of total cells
expressing Siglecs 8 days postinfection. c The percentage of CD3
+CD4+ cells also positive for Siglec-5 expression in PBMCs from
patients with recent HIV infection (n010) was analyzed by flow
cytometry and compared to samples from uninfected healthy donors
(n06). Error bars represent SEM








HIV plasma viral load
(log10 copies/mL)
1 19 401 5.5
2 91 870 3.0
3 25 362 5.7
4 76 521 3.8
5 20 425 4.5
6 106 471 5.8
7 29 897 4.9
8 102 862 4.9
9 35 609 3.2
10 75 698 6.2
a Estimated date of infection. All patients were antiretroviral naive
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When compared to HIV-negative controls, recently
infected HIV-1-positive individuals had significant enrich-
ment of Siglec-5-positive CD4+ T cells. Interestingly,
Siglec-6 is upregulated on tissue-like memory B cells of
HIV-viremic individuals [13]. The authors of that study
suggest that Siglec expression is a marker of a dysfunction-
al, anergic phenotype in the setting of immune system
exhaustion. However, another possible interpretation is that
cells expressing Siglecs preferentially survive the height-
ened immune activation and activation-induced cell death
caused by HIV-1 infection. The differences in functionality
of Siglec-positive cells could also reflect their maturational
state. In our HIV-infected cohort, Siglec-5 expression was
mainly detected on naïve CD4+ T cells (data not shown),
which could appear dysfunctional if compared to responses
of mature memory and effector T cells. Thus, instead of
representing an exhausted phenotype, Siglec expression in
this setting may be a marker of differentiation correlating
with a less mature phenotype. Further work is needed to
understand the mechanisms regulating Siglec-5 expression
and its relation to T cell differentiation.
Another recent study [29] concluded that decreased ex-
pression of Siglec-7 on natural killer cells represents an
early marker of dysfunctional NK-cell subsets, associated
with high levels of HIV-1 viremia. These authors suggested
that high frequencies of Siglec-7-negative NK cells might
reflect the immune and clinical status of HIV-1 infection and
can also track the effectiveness of therapy. Interestingly,
they also observed maintenance of Siglec-7-positive NK
cells in long-term nonprogressors. In this uncommon set-
ting, Siglec expression may also contribute to control of
immune activation and delayed disease progression.
The use of lentivirus infection of chimpanzees as a model
for understanding HIV pathogenesis has been further com-
plicated by a long-term natural history study of infected wild
chimpanzees which revealed that, contrary to what was
previously thought, SIVcpz can be pathogenic [4] and may
be associated with chimpanzee population decline [30].
Interestingly, the latter study concludes that population ex-
tinction is not an inevitable consequence of SIVcpz infec-
tion despite negative effects of the virus on population size.
Taken together, the data indicate SIVcpz infection in this
population is less pathogenic than untreated HIV-1 infection
in humans, which was almost always fatal prior to the
availability of antiviral treatments.
These recently observed differences in outcome of
SIVcpz infection in its natural host may appear contradicto-
ry at first, as with in vitro comparisons between human and
chimpanzee T cells, but could be explained by a combina-
tion of factors. Siglec expression is one of these factors that
can tilt the balance in favor of the host but obviously does
not offer complete protection. Also, the results obtained
from comparisons of human and chimp CD4+ T cells in
terms of activation thresholds, susceptibility to infection,
and susceptibility to cytopathic effects can be rather differ-
ent depending on the experimental conditions, i.e., how the
cells are activated, for how long, and what type of virus
strain is used [31]. Clearly, the factors that contribute to
different HIV/SIV infection outcomes in different nonhu-
man primate species are many, and these differences may be
greater than previously thought.
Here, we report on a novel cell-intrinsic factor that may
help protect T cells from activation and HIV-induced cell
death and supports the role of excessive immune activation
as one of the main contributors to CD4 T cell loss. Under-
standing the pathways involved in dampening immune ac-
tivation and that result in protection may lead to novel
therapeutic strategies.
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